TY - JOUR
T1 - High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy
AU - Mangioni, C.
AU - Franceschi, S.
AU - Vecchia, C. La
AU - D'Incalci, M.
PY - 1981
Y1 - 1981
N2 - Out of 33 evaluable patients with advanced ovarian cancer, resistant to extensive poly-chemotherapy, then treated with high-dose im medroxyprogesterone (MPA), five partial responses (15%) were obtained. No partial response was obtained in a comparable group of 30 patients treated with an oral schedule. Four patients (two po, 2 im) had stable disease for at least 3 months, and 16 experienced subjective improvement. Treatment was very well tolerated. This study shows that high-dose MPA has some activity in ovarian cancer, and is worthy of further investigation.
AB - Out of 33 evaluable patients with advanced ovarian cancer, resistant to extensive poly-chemotherapy, then treated with high-dose im medroxyprogesterone (MPA), five partial responses (15%) were obtained. No partial response was obtained in a comparable group of 30 patients treated with an oral schedule. Four patients (two po, 2 im) had stable disease for at least 3 months, and 16 experienced subjective improvement. Treatment was very well tolerated. This study shows that high-dose MPA has some activity in ovarian cancer, and is worthy of further investigation.
UR - http://www.scopus.com/inward/record.url?scp=0019816149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019816149&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(81)90131-1
DO - 10.1016/0090-8258(81)90131-1
M3 - Article
C2 - 6458544
AN - SCOPUS:0019816149
VL - 12
SP - 314
EP - 318
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 3
ER -